Monica Alves

Monica Alves

Auto-generated profile, based on publicly available information

Monica Alves

Universidade Estadual de Campinas – Faculdade de Ciências Médicas, Departamento de Oftalmologia e Otorrinolaringologia – Campinas (SP), Brazil

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in The Ocular Surface
Verified
Journal Article
Closed access
Fiona StapletonFiona Stapleton
Fiona Stapleton
MAMonica Alves
Monica Alves
VBVatinee Y. Bunya
Vatinee Y. Bunya
Isabelle JalbertIsabelle Jalbert
Isabelle Jalbert
KLKaevalin Lekhanont
Kaevalin Lekhanont
Lyndon JonesLyndon Jones
Lyndon Jones

2 June 2025 in American Journal of Ophthalmology
Verified
Journal Article
Open access
LJLyndon Jones
Lyndon Jones
Jennifer P CraigJennifer P Craig
Jennifer P Craig
MMMaria Markoulli
Maria Markoulli
PKPaul Karpecki
Paul Karpecki
EAEsen K. Akpek
Esen K. Akpek
KYKyung Chul Yoon
Kyung Chul Yoon
This report provides an evidence-based review of current strategies to manage dry eye disease (DED). First-line management focuses on methods to replenish, conserve, and stimulate the tear film, with an emphasis on ocular supplements, which remain the cornerstone of DED treatment. Meibomian gland dysfunction, a primary contributor to DED, is typically treated with warm compresses and a wide variety of in-office treatments, including device-driven technologies to warm the eyelids, intense pulsed light therapy, low-level light therapy, and other new and emerging technologies. Lid hygiene treatments include lid wipes, anti-Demodex therapies, blepharoexfoliation, and topical antibiotics. DED caused by certain etiological drivers can benefit from anti-inflammatory therapies, including topical and oral corticosteroids, T-cell immunomodulatory drugs, and a wide variety of pharmacological agents, in addition to biologic tear substitutes such as autologous serum and platelet-rich plasma. Emerging therapies, such as neuromodulation via nasal neurostimulation and novel pharmacological treatments, offer potential future options. Advanced options, including amniotic membrane grafts and complex surgical methods, provide options for severe or refractory cases. Lifestyle modifications, including optimized blinking, dietary supplementation, and environmental adjustments, play a crucial role in long-term management. Patient education and adherence to treatment regimens remain essential for sustained symptom relief. The TFOS DEWS III prescribing algorithm provides an evidence-based framework to offer guidance to clinicians in selecting relevant interventions based on disease etiology that aim to provide targeted management of the relevant DED subtype(s) that an individual is experiencing.

1 October 2008 in The Ocular Surface
Verified
Journal Article
Closed access
Eduardo RochaEduardo Rocha
Eduardo Rocha
MAMonica Alves
Monica Alves
JRJ. David Rios
J. David Rios
DDDarlene A. Dartt
Darlene A. Dartt

14 April 2023 in The Ocular Surface
Verified
Journal Article
Closed access
MAMonica Alves
Monica Alves
PAPenny Asbell
Penny Asbell
MDMurat Dogru
Murat Dogru
GGGiuseppe Giannaccare
Giuseppe Giannaccare
AGArturo Grau
Arturo Grau
FSFiona Stapleton
Fiona Stapleton

1 July 2013 in The Ocular Surface
Verified
Journal Article
Closed access
MAMonica Alves
Monica Alves
EFEllen Carrara Fonseca
Ellen Carrara Fonseca
MAMilena Freitas Alves
Milena Freitas Alves
LMLeonardo Tannus Malki
Leonardo Tannus Malki
GAGustavo Viani Arruda
Gustavo Viani Arruda
Eduardo RochaEduardo Rocha
Eduardo Rocha

21 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MAMonica Alves
Monica Alves
PRPeter Sol Reinach
Peter Sol Reinach
JPJayter Silva Paula
Jayter Silva Paula
ACAntonio Augusto Vellasco e Cruz
Antonio Augusto Vellasco e Cruz
LBLeticia Bachette
Leticia Bachette
Eduardo RochaEduardo Rocha
Eduardo Rocha
This study compares signs, symptoms and predictive tools used to diagnose dry eye disease (DED) and ocular surface disorders in six systemic well-defined and non-overlapping diseases. It is well known that these tests are problematic because of a lack of agreement between them in identifying these conditions. Accordingly, we provide here a comparative clinical profile analysis of these different diseases. A spontaneous and continuous sample of patients with Sjögren's syndrome (SS) (n = 27), graft-versus-host-disease (GVHD) (n = 28), Graves orbitopathy (n = 28), facial palsy (n = 8), diabetes mellitus without proliferative retinopathy (n = 14) and glaucoma who chronically received topical drugs preserved with benzalkonium chloride (n = 20) were enrolled. Evaluation consisted of a comprehensive protocol encompassing: (1) structured questionnaire - Ocular Surface Disease Index (OSDI); (2) tear osmolarity (TearLab Osmolarity System - Ocusense); (3) tear film break-up time (TBUT); (4) fluorescein and lissamine green staining; (5) Schirmer test and (6) severity grading. One hundred and twenty five patients (aged 48.8 years-old±14.1, male:female ratio = 0.4) were enrolled in the study, along with 24 age and gender matched controls. Higher scores on DED tests were obtained in Sjögren Syndrome (P<0.05), except for tear film osmolarity that was higher in diabetics (P<0.001) and fluorescein staining, that was higher in facial palsy (P<0.001). TFBUT and OSDI correlated better with other tests. The best combination of diagnostic tests for DED was OSDI, TBUT and Schirmer test (sensitivity 100%, specificity 95% and accuracy 99.3%). DED diagnostic test results present a broad range of variability among different conditions. Vital stainings and TBUT correlated best with one another whereas the best test combination to detect DED was: OSDI/TBUT/Schirmer.